The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Trends in first-line TKI prescribing preferences (PPrefs) among U.S.-based hematology-oncology physicians (HOPs) for patients with chronic phase chronic myelogenous leukemia (CP-CML).
Neil P. Shah
Research Funding - ARIAD; Bristol-Myers Squibb
Arden Buettner
No relevant relationships to disclose
Maria Lankford
No relevant relationships to disclose
Joanne Willey
No relevant relationships to disclose
Doug B. Neely
No relevant relationships to disclose
Mark R. Green
No relevant relationships to disclose